Trump Impact on Medicare Drug Price Negotiations Uncertain
Trump has reversed some of President Biden’s initiatives, including $2 monthly out-of-pocket cap on some generics and experimental pricing models for gene therapies. But so far the healthcare elements of the Inflation Reduction Act remain unchanged.
Funding cuts and regulatory changes could radically reduce Medicaid, the largest program providing medical and health-related ...
The new Trump administration should seize the opportunity to change the Medicare drug price negotiation program by ...
The feds intend to appeal a judge's decision that would force them to recalculate UnitedHealthcare's Medicare Advantage (MA) ...
In November, a federal judge ordered CMS to recalculate UnitedHealthcare's Medicare Advantage Star Ratings for the 2025 plan ...
Medicare will soon negotiate prices for 15 more drugs as part of an effort to reduce costs for seniors and people with ...
The Centers for Medicare and Medicaid Services (CMS) has included Ozempic among the next 15 drugs chosen for Medicare ...
The Biden administration’s last MA rule is a boon for insurers, though it remains to be seen how the incoming Trump ...
Donald Trump has rescinded an executive order from President Joe Biden that sought to lower the price of drugs.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback